uniQure N.V. (LON:0EE0)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 2.36B +233.6% |
| Revenue (ttm) | 14.07M +30.2% |
| Net Income | -190.09M |
| EPS | -3.04 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,886 |
| Open | 46.41 |
| Previous Close | 46.49 |
| Day's Range | 45.08 - 46.41 |
| 52-Week Range | 7.50 - 71.16 |
| Beta | 0.94 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About uniQure
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase ... [Read more]
Financial Performance
In 2025, uniQure's revenue was $16.10 million, a decrease of -40.64% compared to the previous year's $27.12 million. Losses were -$198.97 million, -16.94% less than in 2024.
Financial numbers in USD Financial StatementsNews
uniQure seeks US approval for Huntington's gene therapy after FDA reversal
Dutch gene therapy developer uniQure said on Wednesday it had applied for U.S. approval of its experimental treatment for Huntington's disease after the FDA reversed its earlier position on the drug,...
uniQure submits biologics license application to FDA for ifezuntirgene inilparvo
uniQure (QURE) announced the submission of a biologics license application, or BLA, to the FDA for the accelerated approval of ifezuntirgene inilparvovec, an investigational gene therapy for the treat...
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington's Disease
~ Company also announces the submission of a Marketing Authorisation Application for ifezuntirgene inilparvovec in the U.K. ~ ~ Both submissions are supported by the three-year data analysis from the ...
uniQure resumed with an Outperform at William Blair
William Blair resumed coverage of uniQure (QURE) with an Outperform rating and $73 fair value estimate. The firm sees a “clearer pathway” to FDA approval for AMT-130 in Huntington’s disease.
uniQure price target lowered to $60 from $65 at Barclays
Barclays lowered the firm’s price target on uniQure (QURE) to $60 from $65 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q2…
Wolfe upgrades uniQure to Outperform, sees ‘clear path to approval’ for AMT-130
As previously reported, Wolfe Research upgraded uniQure (QURE) to Outperform from Peer Perform with a $65 price target The stock has priced in less than 50% odds of success for…
uniQure upgraded to Outperform from Peer Perform at Wolfe Research
Wolfe Research upgraded uniQure (QURE) to Outperform from Peer Perform with a $65 price target
uniQure Earnings Call Transcript: Q2 2026
Regulatory alignment with FDA and MHRA enables near-term BLA submission for AMT-130, while early data from Fabry and epilepsy programs support continued development. Financial position is strong with $810.3 million in cash, funding operations into 2030.
uniQure Earnings release: Q2 2026
uniQure released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
uniQure Quarterly report: Q2 2026
uniQure has published its Q2 2026 quarterly earnings report on July 29, 2026.
uniQure reports Q2 EPS ($1.22), consensus (71c)
Reports Q2 revenue $5.84M, consensus $4.71M. “This has been a defining quarter – not just for uniQure (QURE), but for the Huntington’s disease community,” said Matthew Kapusta, chief executive officer...
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington's disease on track as planned for the third quarter of 2026 ~ ~ Topline four-year data from the Phase I/II study of AMT-130 expected i...
uniQure to Announce Second Quarter 2026 Financial Results
~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~ ~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~
uniQure price target raised to $80 from $50 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on uniQure (QURE) to $80 from $50 and keeps a Buy rating on the shares. The firm believes the June 17 regulatory update…
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...
uniQure price target raised to $68 from $35 at Mizuho
Mizuho raised the firm’s price target on uniQure (QURE) to $68 from $35 and keeps an Outperform rating on the shares. Following a recent FDA Type B meeting, the firm…
uniQure 4.95M share Spot Secondary priced at $45.50
The deal size was increased to $225M from $150M and priced below the last closing price of $49.04 per share. Leerink and Stifel are acting as joint book running managers…
uniQure Announces Pricing of Upsized $225 Million Public Offering
LEXINGTON, Mass. and AMSTERDAM, June 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...
UniQure Stock (QURE) Gains on Public Offering Plans
UniQure stock was up after the company revealed plans for a public offering of its shares.
uniQure announces $150M offering of common stock
Leerink Partners and Stifel are acting as bookrunning managers for the proposed offering.
uniQure Announces $150 Million Proposed Public Offering
LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...
uniQure reports preliminary data on first cohort in Phase I/IIa trial of AMT-260
uniQure (QURE) announced initial six-month follow-up data on the first, low dose cohort of six patients in its ongoing Phase I/IIa trial of an investigational gene therapy candidate, AMT-260, for…
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early biological signals of potential therapeutic activity ~
Barclays upgrades uniQure, calls BLA submission ‘major positive’
As previously reported, Barclays upgraded uniQure (QURE) to Overweight from Equal Weight with a price target of $65, up from $25, calling yesterday’s update around plans to file a BLA…